Latest Intelligence on Diabetes in Europe

Published within

« | 1 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Type 2 diabetes driving epidemic

Type 2 diabetes poses one of the greatest public health threats of the 21st century. As well as increasing the potential patient population, type 2 diabetes has also raised the profile of the disease. However, a new Datamonitor report estimates that while 55 million people are affected by type 2 diabetes, only 50% of patients are diagnosed, and only 80% of those actually receive treatment.

Published By Datamonitor
21 Feb 2008
CommentWire
CommentWire

Novo Nordisk: setback for inhaled insulin

Denmark-based Novo Nordisk has dropped its fast-acting mealtime inhaled insulin product AERx due to a lack of commercial potential, and will focus on long-acting inhaled formulations instead. The problems faced by Novo in marketing the drug, including low satisfaction levels and re-imbursement issues with healthcare providers will also apply to other companies developing inhaled insulin systems.

Published By Datamonitor
16 Jan 2008
Expert View
Expert View

Johnson & Johnson: can canagliflozin do what dapa didn't?

New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.

Published By Datamonitor
14 Jun 2012
CommentWire
CommentWire

GlaxoSmithKline: Avandia's future questioned following US report

GlaxoSmithKline is back in the hot seat following the release of a US Senate report that highlights serious health risks associated with its diabetes drug Avandia. The report also criticizes the company for its handling of safety data and although GSK has rejected these claims and issued a fierce defense of its drug, the FDA is now under pressure to order the market withdrawal of Avandia.

Published By Datamonitor
01 Mar 2010
Expert View
Expert View

Autoimmune therapies found wanting in type 1 diabetes

Autoimmune treatments for type 1 diabetes promise to preserve the body's own insulin production. However, three late-stage candidates - teplizumab, otelixizumab, and Diamyd - have failed to show that they can prevent beta-cell destruction in type 1 patients, confirming Datamonitor's long-held belief that there are many barriers to market entry for these treatments.

Published By Datamonitor
03 Jun 2011
Expert View
Expert View

AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting

Well crafted, positive results for AstraZeneca's Brilinta and an unexpected coup for Boehringer Ingelheim's Pradaxa dominated the headlines following this year's European Society of Cardiology's Annual Meeting in Barcelona. Both announcements have a number of important implications for the wider cardiology market, from both therapeutic and commercial perspectives.

Published By Datamonitor
03 Sep 2009
Expert View
Expert View

Amylin's choice of ally for exenatide will be crucial in the wake of its split from Lilly

Having announced an end to its co-development and marketing deal with Eli Lilly covering exenatide antidiabetic products, Amylin is now looking for a bigger partner to drive sales of Byetta and the new once-weekly formulation Bydureon. Datamonitor believes that several major pharmaceutical players meet the criteria to become a suitable ally for the company in its ongoing development of exenatide.

Published By Datamonitor
11 Nov 2011
Expert View
Expert View

Actos suspension could shake up a market already in transition

Takeda's antidiabetic drug Actos has been suspended in France and Germany following study findings which show that it is associated with an increased risk of bladder cancer. Will other countries follow and how will this impact the oral antidiabetics market?

Published By Datamonitor
13 Jun 2011

« | 1 | » »|

No help is available.